Michael Meister

10.1k total citations · 2 hit papers
155 papers, 6.7k citations indexed

About

Michael Meister is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Michael Meister has authored 155 papers receiving a total of 6.7k indexed citations (citations by other indexed papers that have themselves been cited), including 61 papers in Pulmonary and Respiratory Medicine, 46 papers in Oncology and 44 papers in Molecular Biology. Recurrent topics in Michael Meister's work include Lung Cancer Treatments and Mutations (40 papers), Cancer Genomics and Diagnostics (25 papers) and Lung Cancer Research Studies (18 papers). Michael Meister is often cited by papers focused on Lung Cancer Treatments and Mutations (40 papers), Cancer Genomics and Diagnostics (25 papers) and Lung Cancer Research Studies (18 papers). Michael Meister collaborates with scholars based in Germany, Austria and United States. Michael Meister's co-authors include Thomas Muley, Arne Warth, Frédéric Laquai, Michael Thomas, Ian A. Howard, Philipp A. Schnabel, Hendrik Dienemann, Marc A. Schneider, Ralf Mauer and Hans Hoffmann and has published in prestigious journals such as Cell, Journal of the American Chemical Society and Nature Communications.

In The Last Decade

Michael Meister

153 papers receiving 6.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

SARS ‐CoV‐2 receptor ACE 2 and TMPRSS 2 are primarily expressed in bronchial transient secretory cells

2020 703 citations Soeren Lukassen, Robert Lorenz Chua et al. The EMBO Journal profile →
The Novel Histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification System of Lung Adenocarcinoma Is a Stage-Independent Predictor of Survival

2012 542 citations Arne Warth, Thomas Muley et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael Meister Germany	41	2.5k	1.8k	1.6k	1.4k	847	155	6.7k
Vincenzo Canzonieri Italy	43	2.3k 0.9×	1.1k 0.6×	1.2k 0.7×	2.7k 2.0×	415 0.5×	297	7.1k
Go Watanabe Japan	51	3.3k 1.3×	2.5k 1.4×	868 0.5×	2.5k 1.8×	507 0.6×	515	9.9k
Jeong Hyeon Lee South Korea	42	1.8k 0.7×	794 0.4×	683 0.4×	1.4k 1.0×	985 1.2×	283	6.8k
Jingfeng Liu China	47	2.8k 1.1×	1.1k 0.6×	1.4k 0.9×	973 0.7×	554 0.7×	360	8.1k
Hui Gan Australia	46	1.9k 0.8×	1.2k 0.6×	721 0.4×	2.4k 1.8×	231 0.3×	326	7.5k
Soo Hyun Lee South Korea	43	3.2k 1.3×	917 0.5×	844 0.5×	1.4k 1.0×	121 0.1×	303	7.2k
Jason L. Johnson United Kingdom	46	2.5k 1.0×	882 0.5×	1.7k 1.1×	697 0.5×	600 0.7×	163	7.5k
Patrick Soon‐Shiong United States	37	2.2k 0.9×	782 0.4×	957 0.6×	2.8k 2.1×	171 0.2×	162	7.9k
Tao Wang China	46	4.7k 1.9×	1.7k 0.9×	2.0k 1.3×	2.3k 1.7×	127 0.1×	204	8.4k
Yongyi Zeng China	40	2.4k 1.0×	889 0.5×	805 0.5×	736 0.5×	552 0.7×	222	6.2k

Countries citing papers authored by Michael Meister

Since Specialization

Citations

This map shows the geographic impact of Michael Meister's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Meister with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Meister more than expected).

Fields of papers citing papers by Michael Meister

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Meister. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Meister. The network helps show where Michael Meister may publish in the future.

Co-authorship network of co-authors of Michael Meister

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Meister. A scholar is included among the top collaborators of Michael Meister based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Meister. Michael Meister is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Veith, Carmen, Marc A. Schneider, Albert van der Vliet, et al.. (2023). Differences in Treatment Response in Bronchial Epithelial Cells from Idiopathic Pulmonary Fibrosis (IPF) Patients: A First Step towards Personalized Medicine?. Antioxidants. 12(2). 443–443. 1 indexed citations

Muley, Thomas, Michael Meister, Michael Thomas, et al.. (2023). CYFRA 21-1, CA 125 and CEA provide additional prognostic value in NSCLC patients with stable disease at first CT scan. Tumor Biology. 46(s1). S163–S175. 1 indexed citations

Muley, Thomas, Felix Herth, Claus Peter Heußel, et al.. (2023). Prognostic value of tumor markers ProGRP, NSE and CYFRA 21-1 in patients with small cell lung cancer and chemotherapy-induced remission. Tumor Biology. 46(s1). S219–S232. 8 indexed citations

Barrdahl, Myrto, Yassen Assenov, Anika Hüsing, et al.. (2022). Identification of NHLRC1 as a Novel AKT Activator from a Lung Cancer Epigenome-Wide Association Study (EWAS). International Journal of Molecular Sciences. 23(18). 10699–10699. 3 indexed citations

Trefzer, Timo B., Marc A. Schneider, Katharina Jechow, et al.. (2022). Intratumoral Heterogeneity and Immune Modulation in Lung Adenocarcinoma in Female Smokers and Never Smokers. Cancer Research. 82(17). 3116–3129. 4 indexed citations

Lutz, Johannes, et al.. (2022). Local immunotherapy with the RNA-based immune stimulator CV8102 induces substantial anti-tumor responses and enhances checkpoint inhibitor activity. Cancer Immunology Immunotherapy. 72(5). 1075–1087. 9 indexed citations

Schneider, Marc A., Mark Kriegsmann, H. Winter, et al.. (2022). Lung Adenocarcinoma Cell Sensitivity to Chemotherapies: A Spotlight on Lipid Droplets and SREBF1 Gene. Cancers. 14(18). 4454–4454. 1 indexed citations

Lukassen, Soeren, Robert Lorenz Chua, Timo B. Trefzer, et al.. (2020). SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells. The EMBO Journal. e105114–e105114. 253 indexed citations

Medeiros, Rui, María José Oliveira, Carlos Robalo Cordeiro, et al.. (2020). Germline Genetic Variants of the Renin-Angiotensin System, Hypoxia and Angiogenesis in Non-Small Cell Lung Cancer Progression: Discovery and Validation Studies. Cancers. 12(12). 3834–3834. 1 indexed citations

10.

Lukassen, Soeren, Robert Lorenz Chua, Timo B. Trefzer, et al.. (2020). SARS ‐CoV‐2 receptor ACE 2 and TMPRSS 2 are primarily expressed in bronchial transient secretory cells. The EMBO Journal. 39(10). e105114–e105114. 703 indexed citations breakdown →

11.

Dietz, Steffen, Petros Christopoulos, Lisa Gu, et al.. (2019). Serial liquid biopsies for detection of treatment failure and profiling of resistance mechanisms in KLC1–ALK-rearranged lung cancer. Molecular Case Studies. 5(6). a004630–a004630. 17 indexed citations

12.

Silva, Milene Costa da, et al.. (2019). Iron accumulation in tumor-associated macrophages marks an improved overall survival in patients with lung adenocarcinoma. Scientific Reports. 9(1). 11326–11326. 37 indexed citations

13.

Christopoulos, Petros, Volker Endris, Farastuk Bozorgmehr, et al.. (2018). EML4‐ALK fusion variant V3 is a high‐risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK⁺ non‐small cell lung cancer. International Journal of Cancer. 142(12). 2589–2598. 79 indexed citations

14.

Jabs, Julia, Franziska Maria Zickgraf, Jeongbin Park, et al.. (2017). Screening drug effects in patient‐derived cancer cells links organoid responses to genome alterations. Molecular Systems Biology. 13(11). 156 indexed citations

15.

Schneider, Marc A., Martin Granzow, Arne Warth, et al.. (2015). Glycodelin: A New Biomarker with Immunomodulatory Functions in Non–Small Cell Lung Cancer. Clinical Cancer Research. 21(15). 3529–3540. 45 indexed citations

16.

Arab, Khelifa, Yoon Jung Park, Anders M. Lindroth, et al.. (2014). Long Noncoding RNA TARID Directs Demethylation and Activation of the Tumor Suppressor TCF21 via GADD45A. Molecular Cell. 55(4). 604–614. 222 indexed citations

17.

Warth, Arne, Thomas Muley, Michael Meister, et al.. (2012). The Novel Histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification System of Lung Adenocarcinoma Is a Stage-Independent Predictor of Survival. Journal of Clinical Oncology. 30(13). 1438–1446. 542 indexed citations breakdown →

18.

Singer, Stephan, Mona Malz, Esther Herpel, et al.. (2009). Coordinated Expression of Stathmin Family Members by Far Upstream Sequence Element-Binding Protein-1 Increases Motility in Non–Small Cell Lung Cancer. Cancer Research. 69(6). 2234–2243. 83 indexed citations

19.

Roepman, Paul, Jacek Jassem, Egbert F. Smit, et al.. (2008). An Immune Response Enriched 72-Gene Prognostic Profile for Early-Stage Non–Small-Cell Lung Cancer. Clinical Cancer Research. 15(1). 284–290. 114 indexed citations

20.

Brueckner, Bodo, Carlo Stresemann, Ruprecht Kuner, et al.. (2007). The Human let-7a-3 Locus Contains an Epigenetically Regulated MicroRNA Gene with Oncogenic Function. Cancer Research. 67(4). 1419–1423. 349 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact